Evaxion Biotech A/S
(EVAX)
undefined
undefined%
At close: undefined
0.91
-1.09%
After-hours Jan 03, 2025, 04:00 PM EST
Company Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.
The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.
Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.
The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S
| Country | DK |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Christian Kanstrup M.Sc. |
Contact Details
Address: Dr. Neergaards Vej Horsholm, DK | |
| Website | https://www.evaxion-biotech.com |
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828253 |
| CUSIP Number | 29970R105 |
| ISIN Number | US29970R2040 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Kanstrup M.Sc. | Chief Executive Officer |
| Thomas Frederik Schmidt | Chief Financial Officer |
| Andreas Holm Mattsson | Founder & Chief AI Officer |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 6-K | Filing |
| Dec 26, 2024 | 6-K | Filing |
| Dec 17, 2024 | F-1/A | [Amend] Filing |
| Dec 17, 2024 | 6-K | Filing |
| Dec 12, 2024 | 6-K | Filing |
| Dec 09, 2024 | 6-K | Filing |
| Dec 05, 2024 | F-1/A | [Amend] Filing |
| Dec 03, 2024 | 6-K | Filing |
| Nov 18, 2024 | F-1 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |